Last mentioned: Mar 20, 2026
Federal Review
Health Canada expected to assess provincial compliance and determine potential funding penalties.
Public Health Advisory
Health authorities issue guidance for parents on how to identify and return the product.
Retailer Notification
Pharmacies and retailers begin the process of removing affected lots from shelves.
Deadline Missed
Ontario confirms it will not meet the federal deadline for implementing the NP funding framework.
Recall Announcement
Initial reports confirm nearly 90,000 bottles are affected by a safety recall.
Palliative Care Findings
New research confirms high efficacy rates for mitigating end-of-life distress in oncology settings.
Policy Proposal
Nursing associations submit a framework for a public NP billing model to the Ministry of Health.
Federal Health Accord
Ottawa and Ontario sign a multi-billion dollar bilateral health agreement with primary care targets.
Phase 3 Trials
Large-scale multi-site trials aim to provide definitive data for regulatory approval.
SAP Expansion
Canada formally expands the Special Access Program to include restricted psychedelic substances.
SAP Expansion
Canada amends the Special Access Program to include restricted psychedelic substances.
Canadian Exemptions
Health Canada grants the first legal exemptions for psilocybin use to four terminally ill patients.
Regulatory Shift
Health Canada begins granting Section 56 exemptions for terminally ill patients.
FDA Breakthrough Status
FDA grants Breakthrough Therapy designation to psilocybin for treatment-resistant depression.
Foundational Research
Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.
A major recall involving nearly 90,000 bottles of children’s liquid pain medication has been launched across North America. The recall highlights critical safety concerns regarding pediatric dosage accuracy and quality control in the over-the-counter pharmaceutical sector.
A major recall affecting approximately 90,000 bottles of children's liquid pain medication has been initiated across North American markets. The move highlights ongoing vulnerabilities in pediatric pharmaceutical manufacturing and potential supply disruptions for essential over-the-counter treatments.
Ontario has failed to meet a critical federal deadline to establish a public funding framework for nurse practitioners, a move that threatens to stall primary care expansion. The delay highlights the ongoing friction between provincial healthcare delivery and federal mandates aimed at reducing private-pay medical services.
Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
Clinical research into psilocybin-assisted therapy is demonstrating significant potential in mitigating existential distress and depression among terminally ill patients. These findings are driving a re-evaluation of palliative care protocols and accelerating the push for expanded regulatory access to psychedelic-based treatments.